Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced new positive real-world results from its two registry studies evaluating the Company’s proprietary Sebacia Microparticles in Europe and the U.S. The results were presented at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting in two oral presentations.

Read More